Teriflunomide - MS Research Australia

Teriflunomide

Teriflunomide

Administration Route: Oral
Injection site:
Frequency: Daily
TGA approval date: Nov 2012
PBS listed: Yes
Mechanism of action Teriflunomide blocks the activation and proliferation of stimulated lymphocytes which need de novo synthesis of pyrimidine to expand. Slowly dividing or resting cells which rely on the salvage pathway for pyrimidine synthesis are unaffected by teriflunomide.
%reduction in relapse rate, impact of progression 69% reduction in lesions, 53% reduction ARR, 38% decrease in disability progression, reduced disability progression in two years by 49%.
Pregnancy Category X
Safe in Pregnancy Category X -High risk of causing permanent damage to the fetus that they should not be used in pregnancy or when there is a possibility of pregnancy.
Breastfeeding (information predominantly from  LACTMED database) Because there is no published experience with teriflunomide during breastfeeding, it should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.
Monitoring requirements Full blood count and liver function test every 4-8 wks
Potential side effects (not a comprehensive list) Nausea, diarrhoea, hair thinning and elevation of alanine aminotransferase levels.
Manufacturer Sanofi Genzyme
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search